Whilst advanced cancer has proven to be more resistant, early stage disease (such as localised breast cancer, which is commonly cured with a combination of surgery, radiotherapy and hormone therapy) remains challenging to treat using cellular therapies, due to the requirement for highly toxic lymphodepleting conditioning (often incorporating cyclophosphamide with fludarabine) with or without the administration of systemic cytokines such as IL-2. Here, IL2 is linked to cancer.